Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease 

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease  The ATTENTION-AD extension study will offer the 450 patients enrolled in the on-going Phase 2b/3 ANAVEX®2-73 73 (blarcamesine) Early Alzheimer’s disease study the opportunity to continue their treatment for an additional two years and will provide additional tolerability and efficacy data  …

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease NEW YORK – October 2, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s…

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study NEW YORK – September 27, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference NEW YORK – September 26, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central…

Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference   NEW YORK – September 18, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Rett syndrome, Parkinson’s disease, Alzheimer’s disease and other central…

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome Both global efficacy endpoints, RSBQ and CGI-I, showed significant improvement with respect to baseline after 7 weeks of treatment with ANAVEX®2-73 (blarcamesine) ANAVEX®2-73 (blarcamesine) treatment effect was significantly correlated with changes in two…

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019   NEW YORK – September 5, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous…

Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome

Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome NEW YORK – September 4, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett…

 Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results and Provides Clinical Study Updates

 Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results  And Provides Clinical Study Updates Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – August 7, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and…

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019 Conference Call and Webcast To be Held Wednesday August 7, 2019 4:30pm Eastern Time NEW YORK – August 2, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for…